Disease Detail

ID DOID:3369
Name Ewing sarcoma
Definition A bone cancer that has_material_basis in neural crest cells derives_from undeveloped, undifferentiated neuroectoderm.
Source DiseaseOntology.org
Alt Ids DOID:4392 DOID:4390 DOID:0050607 DOID:4980 DOID:4158 DOID:4391
Path disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer bone cancer Ewing sarcoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR1 amp Ponatinib Ewing sarcoma predicted - sensitive detail...
Unknown unknown BMS-754807 Ewing sarcoma not applicable detail...
Unknown unknown Talazoparib + Temozolomide Ewing sarcoma not applicable detail...
Unknown unknown Niraparib + Temozolomide Ewing sarcoma not applicable detail...
Unknown unknown Olaparib + Temozolomide Ewing sarcoma not applicable detail...
Unknown unknown Temozolomide + Veliparib Ewing sarcoma not applicable detail...
Unknown unknown SN-38 + Veliparib Ewing sarcoma not applicable detail...
Unknown unknown Olaparib + SN-38 Ewing sarcoma not applicable detail...
Unknown unknown Niraparib + SN-38 Ewing sarcoma not applicable detail...
Unknown unknown SN-38 + Talazoparib Ewing sarcoma not applicable detail...
Unknown unknown Olaparib + SN-38 + Temozolomide Ewing sarcoma not applicable detail...
Unknown unknown UAB30 Ewing sarcoma not applicable detail...
Unknown unknown GSK1904529A Ewing sarcoma not applicable detail...
Unknown unknown JQ1 Ewing sarcoma not applicable detail...
Unknown unknown MEDI-573 + Vistusertib Ewing sarcoma not applicable detail...
Unknown unknown MEDI-573 + Sirolimus Ewing sarcoma not applicable detail...
Unknown unknown Pembrolizumab Ewing sarcoma no benefit detail...
Unknown unknown Talazoparib Ewing sarcoma not applicable detail...
Unknown unknown Prexasertib Ewing sarcoma not applicable detail...
Unknown unknown Carfilzomib + Selinexor Ewing sarcoma not applicable detail...
Unknown unknown CUDC-907 Ewing sarcoma not applicable detail...
Unknown unknown Capmatinib Ewing sarcoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00020566 Phase III Busulfan + Melphalan Dactinomycin + Doxorubicin + Etoposide + Ifosfamide + Vincristine Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status
NCT00084695 Phase II Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status
NCT00089245 Phase I Omburtamab Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer Recruiting
NCT01241162 Phase I Decitabine Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma Completed
NCT01286987 Phase I Talazoparib Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors Completed
NCT01331135 Phase I Sirolimus Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Active, not recruiting
NCT01396408 Phase II Temsirolimus Sunitinib A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours Active, not recruiting
NCT01661400 Phase I Cyclophosphamide Thalidomide Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors Recruiting
NCT01858168 Phase I Olaparib + Temozolomide Phase I Study of Olaprib and Temozolomide for Ewings Sarcoma Recruiting
NCT01946529 Phase II Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Vincristine Bevacizumab + Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Irinotecan + Sorafenib + Temozolomide + Temsirolimus + Vincristine Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors Active, not recruiting
NCT02013336 Phase I Cyclophosphamide + MM-398 Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors Recruiting
NCT02044120 Phase I Niraparib + Temozolomide ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide in Patients With Previously Treated, Incurable Ewing Sarcoma Recruiting
NCT02048371 Phase II Regorafenib A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas Recruiting
NCT02116777 Phase Ib/II Talazoparib + Temozolomide BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies Completed
NCT02173093 Phase Ib/II Aldesleukin + GD2Bi-a ATC + Sargramostim Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma Recruiting
NCT02306161 Phase II Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Vincristine Ganitumab Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma Active, not recruiting
NCT02454972 Phase II Lurbinectedin Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors Active, not recruiting
NCT02644460 Phase I Abemaciclib Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors Recruiting
NCT02657005 Phase I TK216 TK216 in Patients With Relapsed or Refractory Ewing Sarcoma Recruiting
NCT02748135 Phase Ib/II TB-403 A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma Recruiting
NCT02867592 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting
NCT02890758 Phase I ALT-803 Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Recruiting
NCT02982941 Phase I MGA271 Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors Completed
NCT03139331 Phase I Irinotecan + Pazopanib + Temozolomide PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma Recruiting
NCT03155620 Phase II Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting
NCT03190174 Phase Ib/II Nab-Rapamycin + Nivolumab Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma Recruiting
NCT03210714 Phase II Erdafitinib Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Recruiting
NCT03213678 Phase II LY3023414 PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Recruiting
NCT03213704 Phase II Larotrectinib Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Recruiting
NCT03221400 Phase Ib/II STA-8666 PEN-866 in Patients With Advanced Solid Malignancies Recruiting
NCT03233204 Phase II Olaparib Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Recruiting
NCT03245151 Phase Ib/II Everolimus + Lenvatinib Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors Recruiting
NCT03441360 Phase II Eribulin Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) Recruiting
NCT03458728 Phase Ib/II Copanlisib Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients Recruiting
NCT03495921 FANG vaccine + Irinotecan + Temozolomide Irinotecan + Temozolomide Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma Recruiting
NCT03514407 Phase I INCB059872 A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma Recruiting
NCT03600649 Phase I SP-2577 Clinical Trial of SP-2577 in Patients With Relapsed or Refractory Ewing Sarcoma Recruiting
NCT03698994 Phase II Ulixertinib Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Recruiting
NCT03709680 Phase I Irinotecan + Palbociclib + Temozolomide Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors Recruiting
NCT03880123 Phase I Ixazomib + Selinexor Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma Not yet recruiting